Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Insights | DelveInsight
11. Juli 2022 12:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 11, 2022 (GLOBE NEWSWIRE) -- Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Insights | DelveInsight Metastatic castration-resistant prostate cancer...
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
17. November 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...
eFFECTOR Initiates Dosing in Phase 2 Trial of Tomivosertib (eFT508) in Advanced Castrate-Resistant Prostate Cancer (CRPC)
11. Dezember 2018 08:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, Dec. 11, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., (eFFECTOR), a leader in the development of selective translation regulators (STRs) for the treatment of cancer, announced...